# A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07681596/  
OnCo record `nct07681596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD4045, Daratumumab, Aldesleukin in multiple myeloma, run by AstraZeneca, now recruiting.

## Summary

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07681596 by AstraZeneca, with 101 participants planned, started 2026-07-27 and due to reach its primary completion in 2031-03-06. Interventions recorded: AZD4045, Daratumumab, Aldesleukin. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07681596
- Phase: 1/2
- Setting: A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
- Sponsor: AstraZeneca
- Enrolled: 101

## Sources

- ClinicalTrials.gov NCT07681596: https://clinicaltrials.gov/study/NCT07681596

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [AZD4045](https://onco.cc/drugs/azd4045/), [Daratumumab](https://onco.cc/drugs/daratumumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07681596.json